Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Longevity Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FOXO3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FOXO3 Recombinant Protein (Wild-Type & Phospho-Resistant Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for PPI and DNA-binding assays. |
View FOXO3 Products |
| Gene Delivery | FOXO3 Promise-ORF / Lentivirus Full-length ORF and nuclear-translocation reporter constructs for stable cell line generation. |
View FOXO3 Products |
| Benchmark Ab | Anti-FOXO3 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View FOXO3 Products |
| Validator | FOXO3 siRNA Set Target-specific knockdown pool for specificity and functional rescue assays. |
View FOXO3 Products |
| Related Target A | AKT1 Upstream master kinase that phosphorylates FOXO3 at T32, S253, and S315, triggering nuclear export and inactivation. |
View AKT1 Products |
| Related Target B | YWHAH (14-3-3 eta) Chaperone protein that binds phosphorylated FOXO3, sequestering it in the cytoplasm. Crucial for PPI inhibitor screening. |
View YWHAH Products |
| Related Target C | SIRT1 NAD+-dependent deacetylase that deacetylates FOXO3, modulating its transcriptional activity toward oxidative stress resistance. |
View SIRT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Phosphoylation-state dependency screening | Site-specific mutant proteins (T32A/S253A/S315A) and wild-type proteins strictly verified by Mass Spectrometry. |
| Nuclear-cytoplasmic translocation tracking | High-titer Lentiviral particles expressing fluorescently tagged FOXO3 for high-content screening (HCS). |
| Lack of reliable positive controls | Sequence-defined recombinant biosimilar antibodies matching clinical-grade benchmark specifications. |
| Off-target transcription factor cross-reactivity | Subfamily counter-screening panel including FOXO1 and FOXO4 proteins with guaranteed high purity (>95%). |
Live FOXO3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the FOXO3 pathway is undergoing a major paradigm shift. Long regarded as an "undruggable" transcription factor, FOXO3 is now at the center of oncology and anti-aging R&D. Because direct activation of transcription factors is challenging, current drug discovery strategies are bifurcated: direct small-molecule modulation of FOXO3 protein-protein interactions (such as disrupting the FOXO3:14-3-3 complex) and indirect modulation via upstream PI3K/AKT/SGK1 pathway inhibitors.
As first-generation AKT inhibitors face clinical limitations due to systemic toxicity, next-generation therapeutics are focusing on highly selective FOXO3 nuclear-translocation promoters and PROTAC-mediated degradation of upstream negative regulators. Moreover, FOXO3's role as a master regulator of longevity and cellular senescence has opened novel therapeutic avenues in regenerative medicine and age-related degenerative diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Collaborations, Biotech Startups | Solid Tumors, Acute Myeloid Leukemia (AML) | FOXO3:14-3-3 binding disruption assays (Requires high-purity WT FOXO3 and YWHAH proteins) |
| Small Molecule (AKT/SGK Inhibitors) | AstraZeneca, Roche, Merck | Breast Cancer, Prostate Cancer | Phospho-specific Western Blot/ELISA validation (Requires sequence-verified phosphorylation-resistant mutants) |
| Gene Therapy / mRNA | Longevity-focused Biotechs | Sarcopenia, Cardiovascular Diseases, Senescence | Overexpression validation (Requires high-titer Lentivirus or sequence-verified ORF clones) |